ArticleMolecular genetics & genomic medicine2026
Exploration of the Pathogenic Mechanism of the Factor XIII A Subunit in a Patient With Congenital Factor XIII Deficiency.
Article in Molecular genetics & genomic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploration of the Pathogenic Mechanism of the Factor XIII A Subunit in a Patient With Congenital Factor XIII Deficiency.Molecular genetics & genomic medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundCongenital factor XIII (FXIII) deficiency is an extremely rare autosomal recessive blood clotting disorder with an incidence of approximately one in two million, which is caused mainly by mutations in the F13A1 gene. Recently, we identified a Chinese family with FXIII deficiency carrying a likely pathogenic variant and explored its pathogenic mechanism.
aimThe aim of this study was to investigate the pathogenic mechanism associated with the Ser414 mutation in the F13A1 gene.
methodsWe performed clinical diagnosis, phenotypic assessment, and genetic analysis of the proband and her family members.
resultsThe FXIII antigen level of the proband was 1.3%, which was significantly lower than the normal reference range. A mutation was identified through targeted next-generation sequencing (NGS). The effects of these variations on protein function were assessed using bioinformatics tools. Homology analysis revealed that Ser414 was also highly conserved in homologous species. Protein model analysis revealed that the Ser414Leu variation could induce alterations in the spatial structure of F13A1, potentially increasing its instability. This is the first time that F13A1 gene variants have been analyzed in a patient with FXIII deficiency, contributing to the expansion of the pathogenic variant database for congenital FXIII deficiency.
conclusionThese findings provide valuable data accumulation that can contribute to the prevention of congenital FXIII deficiency, the exploration of potential pathogenic mechanisms, and the enrichment of genetic mutation databases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.